If you’re aspiring to lead a rheumatology department, you will need more than what you learned in medical school. Beyond expertly treating patients and participating in research, these leaders must also understand management, mentorship and problem solving, as well as the business of running a successful department…
(Reuters Health)—Patients who live in low-income communities and lack a college education may have worse pain after knee replacement surgery than their more educated neighbors, a recent study suggests. Two years after total knee replacement surgeries, patients in poor communities who hadn’t gone to college had average pain scores that were about 10 points worse…
Sandra Mintz, MSN, RN, knew in high school that she wanted to be a nurse, and upon graduation, she did just that, the youngest in her class to graduate from Pasadena City College with an Associate of Science in nursing. Not long after embarking on her career, she received a life-altering medical diagnosis of her…
RISE now has three means of reporting through the Merit-Based Incentive Payment System (MIPS): individual, group and the recently added virtual groups. According to the CMS, virtual groups allow individual MIPS-eligible clinicians or groups consisting of not more than 10 MIPS-eligible clinicians to join together and report as if they were a single entity. The…
The Rheumatology Clinical Registry (RCR) is open for reporting. As we are approaching the end of the 2017 MIPS performance year, however, keep in mind that to report via the RCR, your last date to enter patient information will be Jan. 15, 2018. You can access the RCR’s updated dashboard here. Remember to use your…
Medicare’s Merit-Based Incentive Payment System (MIPS) has been on a gradual incline toward requiring full participation by eligible providers. During its transition stage, reporting for the first year (2017) allowed providers the option to report as partial, full, minimum or not at all, with varying degrees of penalties and incentives across all three reporting components:…
In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…
The introduction of biologic disease-modifying anti-rheumatic drugs (DMARDs) has greatly expanded the treatment options for managing rheumatoid arthritis (RA). In many patients, biologic DMARDs improve clinical symptoms, improve function and slow disease progression. Biologic DMARDs are recommended as add-on treatment to conventional synthetic DMARDs, such as methotrexate (MTX) in patients who experienced an incomplete response…
(Reuters Health)—Many outcomes for hospital patients—including how long they stay and their survival odds after they go home—may depend on whether or not they’re cared for by their primary care physician, a U.S. study suggests. Researchers examined data on 560,651 admissions nationwide for patients covered by Medicare, the U.S. health program for the elderly and…
(Reuters)—U.S. drugstore chain operator CVS Health Corp said on Sunday it had agreed to acquire U.S. health insurer Aetna Inc. for $69 billion, seeking to tackle soaring healthcare spending through lower-cost medical services in pharmacies. This year’s largest corporate acquisition will combine one of the nation’s largest pharmacy benefits managers (PBMs) and pharmacy operators with…